FCH
AVTX icon

Freestone Capital Holdings’s Avalo Therapeutics AVTX Stock Holding History

Freestone Capital Holdings’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$34K – 583
2021
Q4 		$34K Buy
+7
New +$42K ﹤0.01% 500

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Freestone Capital Holdings's AVTX Position: Q1 2022 in Review

Freestone Capital Holdings sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 7 shares — an estimated $34K sold.

Freestone Capital Holdings first reported a position in AVTX in Q4 2021 and held it in 1 quarter. The position peaked at $34K in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • Freestone Capital Holdings reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Freestone Capital Holdings sold 7 Avalo Therapeutics shares in Q1 2022, an estimated $34K.
  • Freestone Capital Holdings first reported a position in Avalo Therapeutics in Q4 2021 and held it in 1 quarter.
  • Freestone Capital Holdings's Avalo Therapeutics position peaked at $34K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on Freestone Capital Holdings's 13F filing for Q1 2022, filed 12 May 2022.